OTCMKTS:RKAGY - RHOEN-KLINIKUM/ADR Stock Price, News & Analysis

$12.28
-0.63 (-4.88 %)
(As of 08/18/2019 09:50 AM ET)
Today's Range
$12.28
Now: $12.28
$12.28
50-Day Range
$12.68
MA: $13.75
$15.04
52-Week Range
$11.60
Now: $12.28
$15.04
Volume102 shs
Average Volume721 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, builds, acquires, and operates primarily acute-care hospitals in Germany. Its hospitals offer treatment services primarily in the areas of cardiovascular, neurology, oncology, pulmonology, orthopedic, accident surgery; rehabilitation and nursing services to the elderly; and thoracic, tumors, and psychosomatic, as well as spinal, column, and joints diseases. As of December 31, 2018, it operated 11 hospitals and 5,369 beds/places at 5 medical sites. The company is headquartered in Bad Neustadt an der Saale, Germany.

Industry, Sector and Symbol

Industry Medical Care
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RKAGY
CUSIPN/A
CIKN/A
Phone49 9771 65 0

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees9,384
Next Earnings DateN/A
OptionableNot Optionable

Receive RKAGY News and Ratings via Email

Sign-up to receive the latest news and ratings for RKAGY and its competitors with MarketBeat's FREE daily newsletter.


RHOEN-KLINIKUM/ADR (OTCMKTS:RKAGY) Frequently Asked Questions

What is RHOEN-KLINIKUM/ADR's stock symbol?

RHOEN-KLINIKUM/ADR trades on the OTCMKTS under the ticker symbol "RKAGY."

Has RHOEN-KLINIKUM/ADR been receiving favorable news coverage?

Media coverage about RKAGY stock has trended negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. RHOEN-KLINIKUM/ADR earned a news impact score of -2.3 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for RHOEN-KLINIKUM/ADR.

Who are some of RHOEN-KLINIKUM/ADR's key competitors?

Who are RHOEN-KLINIKUM/ADR's key executives?

RHOEN-KLINIKUM/ADR's management team includes the folowing people:
  • Mr. Stephan Holzinger, Chairman of Board of Management & CEO
  • Prof. Bernd Griewing, Chief Medical Officer & Member of Board of Management
  • Dr. Gunther Karl Weiß, COO & Member of Management Board (Age 53)
  • Mr. Jörg Demmler, Head of Technical Controlling & Environment (Age 67)
  • Julian Schmitt, Head of Investor Relation

How do I buy shares of RHOEN-KLINIKUM/ADR?

Shares of RKAGY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is RHOEN-KLINIKUM/ADR's stock price today?

One share of RKAGY stock can currently be purchased for approximately $12.28.

What is RHOEN-KLINIKUM/ADR's official website?

The official website for RHOEN-KLINIKUM/ADR is http://www.rhoen-klinikum-ag.com/.

How can I contact RHOEN-KLINIKUM/ADR?

The company can be reached via phone at 49 9771 65 0.


MarketBeat Community Rating for RHOEN-KLINIKUM/ADR (OTCMKTS RKAGY)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  92
MarketBeat's community ratings are surveys of what our community members think about RHOEN-KLINIKUM/ADR and other stocks. Vote "Outperform" if you believe RKAGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKAGY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: What is a Buy-Side Analyst?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel